HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced its HTG EdgeSeq technology was highlighted in multiple posters presented by global pharma company partners at the American Association for Cancer Research (AACR) 2020 Virtual Meeting.
“We were pleased to see our technology highlighted in two additional abstracts at this year’s AACR virtual meeting,” said Byron Lawson, Senior Vice President and Chief Commercial Officer. “It is very satisfying to see our pharma partners enhancing their research and findings with our HTG EdgeSeq technology, and we look forward to continuing to build on this momentum.”
Posters presented at the 2020 Virtual AACR meeting using HTG EdgeSeq technology include:
- Comparison of HTG-Edge targeted RNA sequencing platform with whole transcriptome RNA sequencing for clinical biomarker studies; and
- Pan-cancer gene expression analysis of tissue microarray using HTG EdgeSeq Oncology Biomarker Panel and a cross-comparison with ERBB3 immunohistochemical analysis.
“These posters highlighting our technology at this year’s AACR conference are a testament to the utility of our technology,” said John Lubniewski, President and CEO of HTG. “These posters, combined with those released at ASCO in May 2020, demonstrate how partners and collaborators globally are leveraging our technology to take their science to new heights.”